Dr Niamh Buckley is working to develop a treatment for triple negative breast cancer, using technology similar to that used in the COVID-19 vaccine.

Professor Ester Hammond is studying how changing oxygen levels in triple negative breast cancer can make the disease more aggressive and likely to spread. 

Professor Leonie Young is working to determine whether some secondary breast cancers that have spread to the brain could be treated with drugs called PARP inhibitors. She hopes that more people could benefit from this type of treatment.

Professor Janet Brown wants to determine if combining an immunotherapy drug avelumab with another drug, radium-233, could make the treatment more effective. She hopes this combination will improve the immune response to secondary breast cancer in the bone and at other sites in the body.

It’s thought that turning on the androgen receptor in some oestrogen receptor positive (ER+) breast cancers could help stop tumour growth. Dr Violeta Serra is investigating this theory further and is testing whether the androgen receptor could be a new treatment target.

Palbociclib is a drug given to people with secondary, oestrogen receptor positive (ER+) breast cancer to help manage their disease. Dr Saskia Wilting is trying to find out who will benefit from taking this drug and why some cancers do not respond to it.